

GT Biopharma secures FDA IND clearance for GTB-5550, advancing its TriKE therapy into Phase 1 clinical trials for multiple myeloma.
You can purchase shares of GT Biopharma (NASDAQ:GTBP) through any online brokerage.
Other companies in GT Biopharma’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
GT Biopharma has a consensus price target of $275.00.
The stock price for GT Biopharma (NASDAQ: GTBP) is $2.77 last updated November 20, 2026 at 6:03 PM EST.
There are no upcoming dividends for GT Biopharma.
GT Biopharma does not have any upcoming earnings scheduled.
There is no upcoming split for GT Biopharma.
GT Biopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing...